BioCryst Pharmaceuticals, Inc. (BCRX) Shares Sold by Artal Group S.A.
Artal Group S.A. lessened its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 23.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 650,000 shares of the biotechnology company’s stock after selling 200,000 shares during the period. Artal Group S.A. owned 0.66% of BioCryst Pharmaceuticals worth $3,406,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also modified their holdings of the company. Principal Financial Group Inc. raised its position in shares of BioCryst Pharmaceuticals by 0.3% during the 1st quarter. Principal Financial Group Inc. now owns 13,250 shares of the biotechnology company’s stock worth $111,000 after acquiring an additional 45 shares in the last quarter. Legal & General Group Plc increased its position in BioCryst Pharmaceuticals by 4.9% during the second quarter. Legal & General Group Plc now owns 18,346 shares of the biotechnology company’s stock worth $102,000 after buying an additional 860 shares during the period. Fox Run Management L.L.C. acquired a new position in BioCryst Pharmaceuticals during the second quarter worth approximately $126,000. Bank of America Corp DE increased its position in BioCryst Pharmaceuticals by 43.3% during the first quarter. Bank of America Corp DE now owns 25,029 shares of the biotechnology company’s stock worth $210,000 after buying an additional 7,568 shares during the period. Finally, Los Angeles Capital Management & Equity Research Inc. acquired a new position in BioCryst Pharmaceuticals during the third quarter worth approximately $132,000. 72.06% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “BioCryst Pharmaceuticals, Inc. (BCRX) Shares Sold by Artal Group S.A.” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/11/20/biocryst-pharmaceuticals-inc-bcrx-shares-sold-by-artal-group-s-a.html.
In other news, Director Fred E. Cohen sold 54,250 shares of the business’s stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $5.42, for a total value of $294,035.00. Following the transaction, the director now owns 173,660 shares of the company’s stock, valued at $941,237.20. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CMO William P. Sheridan sold 64,310 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $4.72, for a total value of $303,543.20. The disclosure for this sale can be found here. Insiders own 5.60% of the company’s stock.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) traded down $0.11 during trading hours on Monday, hitting $4.52. The stock had a trading volume of 2,299,900 shares, compared to its average volume of 1,568,436. The company has a current ratio of 2.53, a quick ratio of 2.53 and a debt-to-equity ratio of 0.21. BioCryst Pharmaceuticals, Inc. has a 1-year low of $3.95 and a 1-year high of $9.25.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.18). The business had revenue of $8.76 million for the quarter, compared to analyst estimates of $5.05 million. BioCryst Pharmaceuticals had a negative return on equity of 123.16% and a negative net margin of 167.58%. The company’s revenue for the quarter was up 12.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.16) earnings per share. equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.72 earnings per share for the current year.
Several research firms have commented on BCRX. Noble Financial reaffirmed a “buy” rating on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 8th. HC Wainwright reaffirmed a “buy” rating on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 8th. ValuEngine lowered BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, August 10th. BidaskClub raised BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $15.00 price target (up previously from $13.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, September 5th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the stock. BioCryst Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $9.13.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.